A Sensitive ALK Immunohistochemistry Companion Diagnostic Test Identifies Patients Eligible for Treatment with Crizotinib-Reference-Cited by-同舟云学术

A Sensitive ALK Immunohistochemistry Companion Diagnostic Test Identifies Patients Eligible for Treatment with Crizotinib

Published:2017-05 Issue:5 Volume:12 Page:804-813
ISSN:1556-0864
Container-title:Journal of Thoracic Oncology
language:en
Short-container-title:Journal of Thoracic Oncology

Author:

Thorne-Nuzzo Trish,Williams Crystal,Catallini Alice,Clements June,Singh Shalini,Amberson James,Dickinson Kim,Gatalica Zoran,Ho Steffan N.,Loftin Isabell,McElhinny Abigail,Towne Penny

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Oncology

Reference28 articles.

1. Howlander N, Noone A, Krapcho M. SEER cancer statistics review. http://seer.cancer.gov/csr/1975_2010. Accessed September 10, 2013.

2. Survival by histologic subtype in stage IV nonsmall cell lung cancer based on data from the Surveillance, Epidemiology and End Results Program;Cetin;Clin Epidemiol,2011

3. The diagnostic value of circulating cell free DNA quantification in non-small cell lung cancer: a systematic review with meta-analysis;Jiang;Lung Cancer,2016

4. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer;Soda;Nature,2007

5. Identification of novel isoforms of the EML4-ALK transforming gene in non-small cell lung cancer;Choi;Cancer Res,2008

Cited by 49 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Revisiting ALK (D5F3) immunohistochemistry: Insights into focal staining and neuroendocrine differentiation;Thoracic Cancer;2024-09-10

2. Principles of Analytic Validation of Immunohistochemical Assays: Guideline Update;Archives of Pathology & Laboratory Medicine;2024-02-23

3. Overcoming Central β-Sheet #6 (Cβ6) ALK Mutation (L1256F), TP53 Mutations and Short Forms of EML4-ALK v3/b and v5a/b Splice Variants are the Unmet Need That a Re-Imagined 5th-Generation (5G) ALK TKI Must Deliver;Lung Cancer: Targets and Therapy;2024-02

4. Diagnosis and treatment of anaplastic lymphoma kinase (ALK) rearranged non−small cell lung cancer;Lung Cancer;2024

5. A novel intergenic (between REG3A and CTNNA2-AS1)-ALK fusion responds to alectinib in lung adenocarcinoma;Lung Cancer;2023-12